{
    "organizations": [],
    "uuid": "8af51977a97ced63e1e2f70149527cfe32475f71",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-retrophin-q1-loss-per-share-046/brief-retrophin-q1-loss-per-share-0-46-idUSASC09YPJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Retrophin Q1 Loss Per Share $0.46",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Retrophin Inc:\n* Q1 REVENUE $38 MILLION VERSUS I/B/E/S VIEW $39.3 MILLION * Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.14\n* Q1 EARNINGS PER SHARE VIEW $-0.45 â€” THOMSON REUTERS I/B/E/S\n* PIVOTAL PHASE 3 DUPLEX STUDY OF SPARSENTAN IN FSGS UNDERWAY TO SUPPORT SUBPART H NDA FILING\n* AS OF MARCH 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $264.1 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-02T04:42:00.000+03:00",
    "crawled": "2018-05-02T16:03:43.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "retrophin",
        "inc",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "adjusted",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "pivotal",
        "phase",
        "duplex",
        "study",
        "sparsentan",
        "fsgs",
        "underway",
        "support",
        "subpart",
        "h",
        "nda",
        "filing",
        "march",
        "company",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}